Nausea and vomiting
Nausea and vomiting are among the most common gastrointestinal AEs associated with eribulin therapy. In the EMBRACE study, 35% and 18% of the patients experienced nausea and vomiting, respectively [21]. However, these AEs were usually mild, with grade 3 and 4 toxicities occurring in <1% of patients. A low incidence of both AEs was seen in Study 301 [22]. Although the emetogenic potential of eribulin is common, it is considered low in comparison to that of the other antineoplastic agents such as cisplatin, doxorubicin, and cyclophosphamide [58]. Based on our clinical experience, eribulin-induced nausea and vomiting are relatively uncommon and anti-emetic prophylaxis is usually not necessary for Asian patients. If these AEs do occur, treatment guidelines for managing chemotherapy-induced nausea and vomiting can be followed, such as the guidelines of the Multinational Association of Supportive Care in Cancer, ASCO, and NCCN [5960].